| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 2.665 | 18.078 | 3.916 | 2.494 | 5.407 | 3.944 | 5.483 | 5.538 |
| Total Income - EUR | - | - | 2.699 | 18.079 | 3.918 | 2.494 | 5.482 | 3.944 | 5.486 | 5.697 |
| Total Expenses - EUR | - | - | 6.391 | 8.903 | 4.788 | 662 | 698 | 1.528 | 4.750 | 5.664 |
| Gross Profit/Loss - EUR | - | - | -3.693 | 9.176 | -870 | 1.832 | 4.784 | 2.417 | 735 | 34 |
| Net Profit/Loss - EUR | - | - | -3.773 | 8.634 | -987 | 1.761 | 4.623 | 2.316 | 397 | -236 |
| Employees | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Anamed Nefro Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 525 |
| Current Assets | - | - | 3.280 | 5.641 | 5.179 | 2.796 | 4.991 | 3.165 | 621 | 575 |
| Inventories | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Receivables | - | - | 0 | 0 | 446 | 106 | 452 | 104 | 525 | 33 |
| Cash | - | - | 3.280 | 5.641 | 4.733 | 2.690 | 4.539 | 3.060 | 95 | 541 |
| Shareholders Funds | - | - | -3.729 | 4.973 | -937 | 842 | 4.671 | 3.149 | 446 | 207 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 7.171 | 667 | 6.116 | 1.954 | 320 | 15 | 175 | 893 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Anamed Nefro Srl